Department of Orthopedics Surgery, The Second Affiliated Hospital of Medical College, Zhejiang University, Hangzhou, China.
Thromb Res. 2013 Nov;132(5):531-6. doi: 10.1016/j.thromres.2013.09.005. Epub 2013 Sep 13.
Thromboembolism, including deep venous thrombosis and pulmonary embolism, is a grave threat to patients undergoing total joint replacement. Using a systematic review and meta-analysis we asked whether gene mutations or polymorphisms could be risk factors for thrombosis after arthroplasty.
We performed a comprehensive search of Medline, PubMed, Embase, Cochrane databases, China National Knowledge Infrastructure (CNKI), and Google Scholar, and identified 19 studies detailing genetic investigations of patients with thromboembolism following joint replacement.
Our meta-analyses included 5149 patients who underwent arthroplasty surgery. Significant associations with venous thromboembolism were identified for factor G1691A (odds ratio (OR) 1.41, 95% confidence interval (CI) 1.03 - 1.94, p=0.03), prothrombin G20210A (OR 2.16, 95% CI, 1.27- 3.69, p=0.005), and MTHFR/C677T/TT (OR 2.36, 95% CI 1.03 - 5.42, p=0.04) in Caucasian populations. No significant gene mutation was identified in Asian populations.
This study suggests a way to identify patients scheduled for arthroplasty who are at higher risk of thrombosis, enabling individualized treatment.
血栓栓塞症,包括深静脉血栓形成和肺栓塞,是接受人工关节置换术患者的严重威胁。通过系统评价和荟萃分析,我们探讨了基因突变或多态性是否可能是关节置换术后血栓形成的危险因素。
我们对 Medline、PubMed、Embase、Cochrane 数据库、中国知网(CNKI)和 Google Scholar 进行了全面检索,共确定了 19 项关于关节置换术后血栓形成患者基因研究的研究。
我们的荟萃分析纳入了 5149 名接受关节置换手术的患者。发现因子 G1691A(比值比(OR)1.41,95%置信区间(CI)1.03-1.94,p=0.03)、凝血酶原 G20210A(OR 2.16,95% CI,1.27-3.69,p=0.005)和 MTHFR/C677T/TT(OR 2.36,95% CI 1.03-5.42,p=0.04)与静脉血栓栓塞症显著相关。在亚洲人群中未发现明显的基因突变。
本研究为确定接受关节置换术的高血栓形成风险患者提供了一种方法,有助于实现个体化治疗。